Headquartered in Bedford, MA Fiscal year ends December NASDAQ: OCUL ocutx.com
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company focused on retinal diseases. The company's primary investigational product candidate is AXPAXLI (also known as OTX-TKI), an axitinib intravitreal hydrogel based on its proprietary ELUTYX bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR). The company's commercial product is DEXTENZA, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Ocular also has an investigational product candidate, OTX-TIC, a travoprost intracameral hydrogel that completed a Phase 2 clinical trial for open-angle glaucoma or ocular hypertension. The company trades on NASDAQ under the ticker OCUL. Updated
With a market rotation underway, where should investors seeking opportunities in health care be looking? Analysts have high expectations for Alphatec.
Warren Buffett's Berkshire Hathaway has again bolstered its stake in Occidental Petroleum, and action at Dollar Tree also highlights recent insider buying.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company focused on retinal diseases. The company's primary investigational product candidate is AXPAXLI (also known as OTX-TKI), an axitinib intravitreal hydrogel based on its proprietary ELUTYX bioresorbable hydrogel-based formulation technology.
The Wall Street consensus 12-month price target for OCUL is $26.00.
